Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets (2018 - 2025)

Historic Current Assets for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $738.8 million.

  • Bicycle Therapeutics' Current Assets fell 2353.31% to $738.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.8 million, marking a year-over-year decrease of 2353.31%. This contributed to the annual value of $928.6 million for FY2024, which is 6527.1% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Current Assets of $738.8 million as of Q3 2025, which was down 2353.31% from $804.3 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Current Assets ranged from a high of $1.0 billion in Q2 2024 and a low of $215.4 million during Q1 2021
  • In the last 5 years, Bicycle Therapeutics' Current Assets had a median value of $458.6 million in 2021 and averaged $555.1 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 19446.84% in 2021, then tumbled by 2353.31% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Current Assets (Quarter) stood at $458.6 million in 2021, then fell by 19.45% to $369.4 million in 2022, then skyrocketed by 52.11% to $561.9 million in 2023, then skyrocketed by 65.27% to $928.6 million in 2024, then decreased by 20.44% to $738.8 million in 2025.
  • Its Current Assets stands at $738.8 million for Q3 2025, versus $804.3 million for Q2 2025 and $856.1 million for Q1 2025.